Biomarker Education

ASCP and our partners have worked together to provide the latest pan-tumor education and resources in pathology and laboratory medicine. These new, easily-digestible learning materials are designed to equip you with the most up-to-date information on HER2 testing. Take advantage of these complimentary HER2 learning materials today.

Updates in HER2-directed Therapies in Solid Tumors

This microlearning course is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of emerging research in pan-tumor HER2 testing and of treatment options based on HER2 results. A particular focus of this activity is the DESTINY-Pan Tumor02 study and the latest evidence regarding HER2 testing, scoring and reporting. The microlearning design of this activity allows for a brief and focused exploration of this topic.

Course topics include:

  • HER2-directed therapies
  • DESTINY-PanTumor02 study and FDA approvals
  • HER2 testing, scoring and reporting
  • Treatment implications based on HER2 results

Updates in HER2-directed Therapies in Solid Tumors

Claim Credit

HER2 Testing in Gynecologic Cancers and Implications for Treatment

This microlearning course is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of emerging research in HER2-directed therapies in gynecologic cancers and of treatment options based on HER2 results. A particular focus of this activity is the DESTINY-PanTumor02 study and the latest evidence regarding HER2 testing, scoring and reporting in gynecologic cancers. The microlearning design of this activity allows for a brief and focused exploration of this topic.

Course topics include:

  • DESTINY-PanTumor02 and other trials evaluating HER2-directed therapies in gynecologic cancers
  • HER2 testing and scoring in endometrial, cervical, ovarian cancers
  • Specimen handling, scoring, reporting
  • Treatment implications based on HER2 results

HER2 Testing in Gynecologic Cancers and Implications for Treatment

Claim Credit

HER2 Testing in Other Solid Tumors and Implications for Treatment

This microlearning course is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of emerging research in pan-tumor HER2 testing in patients with advanced solid tumors and of treatment options based on HER2 results.

Course topics include:

  • HER2 signaling pathway
  • HER2 amplification and overexpression and its prevalence in various solid tumors
  • DESTINY-PanTumor02 and the recent FDA pan-tumor approval
  • HER2 IHC scoring guidelines
  • Specimen handing and biomarker reporting
  • HER2 IHC with different antibodies and tumor heterogeneity
  • Treatment implications for patients based on HER2 results

HER2 Testing in Other Solid Tumors and Implications for Treatment

Claim Credit

Take Advantage of These Other HER-2 Activities

Pan-tumor HER2 Tweetorial: HER2 Testing in Advanced Gynecologic Cancers

This tweetorial is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of the latest evidence regarding HER2 testing in advanced gynecologic cancers such as ovarian, cervical, and endometrial cancers.

View Tweetorial

Pan-tumor HER2 Tweetorial: Pan-Tumor HER2 Testing in Advanced Solid Cancers

This tweetorial is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of the latest evidence regarding the role of pan-tumor HER2 testing in advanced solid cancers. HER2 overexpression by IHC is a predictive biomarker for response to a HER2-directed antibody drug conjugate (ADC) in patients with advanced solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

View Tweetorial

These activities are conducted in partnership with Q Synthesis, Society for Gynecological Oncology, and are supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.